PDCD1 and non-small cell lung carcinoma: In this multicenter retrospective study involving 1266 patients with advanced NSCLC, PD‐1 inhibitors demonstrated a statistically significant survival benefit over PD‐L1 inhibitors, with a median OS of 28.2 months compared to 24.6 months (HR 0.74 [95% CI 0.59–0.93]), respectively, reinforcing PD‐1 blockade as the preferred initial therapeutic strategy.